

Fabien Calvo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11074488/publications.pdf>

Version: 2024-02-01

78
papers

9,350
citations

116194

36
h-index

87275

74
g-index

79
all docs

79
docs citations

79
times ranked

16426
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards a cancer mission in Horizon Europe: recommendations. <i>Molecular Oncology</i> , 2020, 14, 1589-1615.	2.1	33
2	Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. <i>Biomedicine Hub</i> , 2020, 5, 1-42.	0.4	15
3	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. <i>Nature Medicine</i> , 2020, 26, 992-994.	15.2	56
4	Towards a Cancer Mission in Horizon Europe. <i>Molecular Oncology</i> , 2019, 13, 2301-2304.	2.1	5
5	Cancer Core Europe: A translational research infrastructure for a European mission on cancer. <i>Molecular Oncology</i> , 2019, 13, 521-527.	2.1	38
6	Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century. <i>European Journal of Cancer</i> , 2018, 103, 155-159.	1.3	15
7	Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort. <i>Npj Breast Cancer</i> , 2017, 3, 4.	2.3	2
8	Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV. <i>Molecular Therapy</i> , 2016, 24, 660-661.	3.7	33
9	AAV2 and Hepatocellular Carcinoma. <i>Human Gene Therapy</i> , 2016, 27, 211-213.	1.4	8
10	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	9.4	1,372
11	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. <i>Nature Genetics</i> , 2015, 47, 1187-1193.	9.4	387
12	EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF. <i>Oncotarget</i> , 2015, 6, 9766-9780.	0.8	30
13	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. <i>Cancer Cell</i> , 2014, 25, 428-441.	7.7	240
14	Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis. <i>Carcinogenesis</i> , 2014, 35, 528-536.	1.3	22
15	Repression of liver colorectal metastasis by the serpin Spn4A a naturally occurring inhibitor of the constitutive secretory proprotein convertases. <i>Oncotarget</i> , 2014, 5, 4195-4210.	0.8	14
16	A novel tumor suppressor function of Kindlin-3 in solid cancer. <i>Oncotarget</i> , 2014, 5, 8970-8985.	0.8	33
17	Î²- and Î±-Cell Dysfunctions in Africans With Ketosis-Prone Atypical Diabetes During Near-Normoglycemic Remission. <i>Diabetes Care</i> , 2013, 36, 118-123.	4.3	32
18	Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. <i>Nature Genetics</i> , 2012, 44, 694-698.	9.4	1,229

#	ARTICLE	IF	CITATIONS
19	EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression. <i>BMC Cancer</i> , 2012, 12, 115.	1.1	29
20	Identification of the Myosin Heavy Polypeptide 9 as a Downstream Effector of the Proprotein Convertases in the Human Colon Carcinoma HT-29 Cells. <i>Methods in Molecular Biology</i> , 2011, 768, 207-215.	0.4	3
21	International network of cancer genome projects. <i>Nature</i> , 2010, 464, 993-998.	13.7	2,114
22	Inhibition of the Proprotein Convertases Represses the Invasiveness of Human Primary Melanoma Cells with Altered p53, CDKN2A and N-Ras Genes. <i>PLoS ONE</i> , 2010, 5, e9992.	1.1	16
23	Soluble Isoforms of Vascular Endothelial Growth Factor Are Predictors of Response to Sunitinib in Metastatic Renal Cell Carcinomas. <i>PLoS ONE</i> , 2010, 5, e10715.	1.1	43
24	Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients. <i>Clinical Cancer Research</i> , 2010, 16, 3288-3295.	3.2	128
25	Distinct expression patterns of the E3 ligase SIAH-1 and its partner Kid/KIF22 in normal tissues and in the breast tumoral processes. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 10.	3.5	23
26	Zebrafish ProVEGF-C Expression, Proteolytic Processing and Inhibitory Effect of Unprocessed ProVEGF-C during Fin Regeneration. <i>PLoS ONE</i> , 2010, 5, e11438.	1.1	20
27	EMMPRIN Promotes Melanoma Cells Malignant Properties through a HIF-2 α Mediated Up-Regulation of VEGF-Receptor-2. <i>PLoS ONE</i> , 2010, 5, e12265.	1.1	29
28	The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2009, 4, 83-91.	0.8	11
29	EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2 α mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. <i>Blood</i> , 2009, 114, 5547-5556.	0.6	95
30	VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. <i>Cancer</i> , 2008, 112, 433-442.	2.0	21
31	Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 915-922.	1.9	67
32	Ketosis-Prone Type 2 Diabetes Mellitus and <i>Human Herpesvirus 8</i> Infection in Sub-Saharan Africans. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 2770.	3.8	90
33	Value of Cytogenetic Analysis in the Treatment of Dermatofibrosarcoma Protuberans. <i>Journal of Clinical Oncology</i> , 2008, 26, 1757-1759.	0.8	25
34	Multitissue Insulin Resistance Despite Near-Normoglycemic Remission in Africans With Ketosis-Prone Diabetes. <i>Diabetes Care</i> , 2008, 31, 2332-2337.	4.3	31
35	Inhibitory Feature of the Proprotein Convertases Prosegments. <i>Medicinal Chemistry</i> , 2008, 4, 116-120.	0.7	6
36	Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. <i>Journal of Clinical Investigation</i> , 2008, 118, 352-363.	3.9	109

#	ARTICLE	IF	CITATIONS
37	Opposing Function of the Proprotein Convertases Furin and PACE4 on Breast Cancer Cells' Malignant Phenotypes: Role of Tissue Inhibitors of Metalloproteinase-1. <i>Cancer Research</i> , 2007, 67, 9030-9034.	0.4	57
38	Extracellular Matrix Metalloproteinase Inducer Up-regulates the Urokinase-Type Plasminogen Activator System Promoting Tumor Cell Invasion. <i>Cancer Research</i> , 2007, 67, 9-15.	0.4	92
39	Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases. <i>Medicinal Research Reviews</i> , 2007, 27, 631-648.	5.0	22
40	Platelets, thrombospondin-1 and human dermal fibroblasts cooperate for stimulation of endothelial cell tubulogenesis through VEGF and PAI-1 regulation. <i>Experimental Cell Research</i> , 2007, 313, 486-499.	1.2	46
41	Consequences of Fetal Exposure to Maternal Diabetes in Offspring. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 3718-3724.	1.8	247
42	Kaposi's Sarcoma-Associated Herpesvirus Viremia is Associated with the Progression of Classic and Endemic Kaposi's Sarcoma. <i>Journal of Investigative Dermatology</i> , 2006, 126, 621-627.	0.3	60
43	Preclinical and Clinical Development of Novel Agents That Target the Protein Kinase C Family. <i>Seminars in Oncology</i> , 2006, 33, 466-478.	0.8	64
44	Proprotein convertases: lessons from knockouts. <i>FASEB Journal</i> , 2006, 20, 1954-1963.	0.2	210
45	Discovery of the Proprotein Convertases and their Inhibitors. , 2006, , 7-26.		0
46	Regulation of the stepwise proteolytic cleavage and secretion of PDGF-B by the proprotein convertases. <i>Oncogene</i> , 2005, 24, 6925-6935.	2.6	67
47	Amphiregulin antisense RNA delivered by adenovirus suppresses growth of breast cancer cells in vitro and in vivo. <i>Chinese Journal of Clinical Oncology</i> , 2005, 2, 533-537.	0.0	1
48	Differential Expression of Extracellular Matrix Metalloproteinase Inducer (CD147) in Normal and Ulcerated Corneas. <i>American Journal of Pathology</i> , 2005, 166, 209-219.	1.9	115
49	Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. <i>Laboratory Investigation</i> , 2004, 84, 1512-1519.	1.7	100
50	Transforming growth factor β -1 and amphiregulin act in synergy to increase the production of urokinase-type plasminogen activator in transformed breast epithelial cells. <i>International Journal of Cancer</i> , 2003, 105, 769-778.	2.3	14
51	SIAH-1 interacts with CtIP and promotes its degradation by the proteasome pathway. <i>Oncogene</i> , 2003, 22, 8845-8851.	2.6	41
52	Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers. <i>Journal of Vascular Surgery</i> , 2003, 38, 1342-1348.	0.6	121
53	Effect of a diabetic environment in utero on predisposition to type 2 diabetes. <i>Lancet, The</i> , 2003, 361, 1861-1865.	6.3	258
54	Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. <i>Cancer Research</i> , 2003, 63, 7575-80.	0.4	84

#	ARTICLE	IF	CITATIONS
55	Prognostic Value of Quantitative Kaposi Sarcoma-associated Herpesvirus Load in Posttransplantation Kaposi Sarcoma. <i>Journal of Infectious Diseases</i> , 2002, 186, 110-113.	1.9	93
56	In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2002, 117, 860-868.	1.2	144
57	Potential mechanisms of resistance to cytarabine in AML patients. <i>Leukemia Research</i> , 2002, 26, 621-629.	0.4	125
58	Expression of high Km 5- α -nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. <i>Blood</i> , 2001, 98, 1922-1926.	0.6	80
59	Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocrine and stromal-epithelial interactions. <i>Journal of Pathology</i> , 2001, 194, 413-419.	2.1	35
60	SIAH-1 interacts with β -tubulin and degrades the kinesin Kid by the proteasome pathway during mitosis. <i>Oncogene</i> , 2000, 19, 5997-6006.	2.6	79
61	Parathyroid Hormone-Related Peptide Stimulates Proliferation of Highly Tumorigenic Human SV40-Immortalized Breast Epithelial Cells. <i>Journal of Bone and Mineral Research</i> , 2000, 15, 2129-2139.	3.1	29
62	Antisense expression for amphiregulin suppresses tumorigenicity of a transformed human breast epithelial cell line. <i>Oncogene</i> , 1999, 18, 6513-6520.	2.6	48
63	Estramustine resistance. <i>General Pharmacology</i> , 1999, 33, 107-113.	0.7	10
64	Estramustine resistance correlates with tau over-expression in human prostatic carcinoma cells. , 1998, 77, 626-631.		25
65	Role of epidermal-growth-factor receptor in tumor progression in transformed human mammary epithelial cells. , 1998, 78, 112-119.		19
66	Association of Estramustine Resistance in Human Prostatic Carcinoma Cells with Modified Patterns of Tubulin Expression. <i>Biochemical Pharmacology</i> , 1998, 55, 325-331.	2.0	31
67	Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. <i>International Journal of Cancer</i> , 1997, 71, 42-48.	2.3	104
68	Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. , 1996, 68, 207-214.		90
69	Loss of chromosome 3p arm differentiating tumorigenic from non-tumorigenic cells derived from the same SV40-transformed human mammary epithelial cells. <i>International Journal of Cancer</i> , 1995, 60, 244-248.	2.3	17
70	Recurrent cytogenetic alterations of prostate carcinoma and amplification of c-myc or epidermal growth factor receptor in subclones of immortalized pnt1 human prostate epithelial cell line. <i>International Journal of Cancer</i> , 1995, 62, 724-731.	2.3	49
71	Characterization of normal breast epithelial cells in primary cultures: Differentiation and growth factor receptors studies. <i>In Vitro Cellular & Developmental Biology</i> , 1992, 28, 716-724.	1.0	24
72	Single-step transformation of human breast epithelial cells by SV40 large T oncogene. <i>International Journal of Cancer</i> , 1992, 52, 92-97.	2.3	34

#	ARTICLE	IF	CITATIONS
73	Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor- β in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 1991, 77, 80-86.	1.2	130
74	Interferon- β in vivo reverses the increased platelet levels of platelet-derived growth factor and transforming growth factor- β in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 1991, 77, 431-435.	1.2	31
75	Histological and urinary reactivity of monoclonal antibody 1be12 in bladder carcinoma. Purification of the antigen from urine. <i>International Journal of Cancer</i> , 1991, 47, 221-226.	2.3	5
76	Estradiol and EGF requirements for cell-cycle progression of normal human mammary epithelial cells in culture. <i>International Journal of Cancer</i> , 1991, 49, 932-937.	2.3	8
77	Effect of gamma interferon on HLA class-I and -II transcription and protein expression in human breast adenocarcinoma cell lines. <i>International Journal of Cancer</i> , 1990, 45, 1169-1176.	2.3	32
78	Characterization, in some human breast cancer cell lines, of gastrin-releasing peptide-like receptors which are absent in normal breast epithelial cells. <i>International Journal of Cancer</i> , 1990, 46, 293-298.	2.3	85